文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Ide-cel或标准方案治疗复发难治性多发性骨髓瘤

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
PubMed 文献 · N Engl J Med · 2023-02-10

这项国际开放标签3期试验将386例既往接受过2–4线治疗且末线难治的复发难治性多发性骨髓瘤患者按2:1随机分配至ide-cel组或五种标准方案之一。中位随访18.6个月时,ide-cel组中位无进展生存期为13.3个月,标准方案组为4.4个月(疾病进展或死亡HR 0.49,95%CI 0.38–0.65,P<0.001);总缓解率分别为71%和42%(P<0.001),完全缓解率分别为39%和5%。总生存数据尚不成熟。

要点

  • ide-cel组中位无进展生存期13.3个月,标准方案组4.4个月(HR 0.49,95%CI 0.38–0.65,P<0.001)。
  • ide-cel组总缓解率71%,标准方案组42%(P<0.001);完全缓解率分别为39%和5%。
  • ide-cel组3–4级不良事件发生率93%,标准方案组75%;细胞因子释放综合征发生率88%。

核心结论

  • 在既往接受过2–4线治疗的三类暴露复发难治性多发性骨髓瘤患者中,ide-cel较标准方案显著延长无进展生存期并改善缓解。
  • ide-cel的毒性与此前报道一致。

研究设计与样本

  • 国际、开放标签、3期随机对照试验。
  • 纳入既往接受过2–4线方案(包括免疫调节剂、蛋白酶体抑制剂和达雷妥尤单抗)且末线治疗难治的成人复发难治性多发性骨髓瘤患者。
  • 按2:1随机分配接受ide-cel(剂量范围150×10^6至450×10^6 CAR阳性T细胞)或五种标准方案之一。
  • 共386例患者随机分组:ide-cel组254例,标准方案组132例。
  • 主要终点为无进展生存期;关键次要终点为总缓解(部分缓解或更好)和总生存期;同时评估安全性。

主要发现

  • 66%的患者为三类难治性疾病,95%为达雷妥尤单抗难治性疾病。
  • 中位随访18.6个月时,ide-cel组中位无进展生存期为13.3个月,标准方案组为4.4个月(疾病进展或死亡HR 0.49,95%CI 0.38–0.65,P<0.001)。
  • ide-cel组71%的患者出现缓解,标准方案组为42%(P<0.001);完全缓解率分别为39%和5%。
  • 总生存数据尚不成熟。
  • ide-cel组3级或4级不良事件发生率为93%,标准方案组为75%。

局限性

  • 总生存数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival is poor among patients with triple-class-exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep, durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma. METHODS: In this international, open-label, phase 3 trial involving adults with relapsed and refractory multiple myeloma who had received two to four regimens previously (including immunomodulatory agents, proteasome inhibitors, and daratumumab) and who had disease refractory to the last regimen, we randomly assigned patients in a 2:1 ratio to receive either ide-cel (dose range, 150×106 to 450×106 CAR-positive T cells) or one of five standard regimens. The primary end point was progression-free survival. Key secondary end points were overall response (partial response or better) and overall survival. Safety was assessed. RESULTS: A total of 386 patients underwent randomization: 254 to ide-cel and 132 to a standard regimen. A total of 66% of the patients had triple-class-refractory disease, and 95% had daratumumab-refractory disease. At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months in the standard-regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P<0.001). A response occurred in 71% of the patients in the ide-cel group and in 42% of those in the standard-regimen group (P<0.001); a complete response occurred in 39% and 5%, respectively. Data on overall survival were immature. Adverse events of grade 3 or 4 occurred in 93% of the patients in the ide-cel group and in 75% of those in the standard-regimen group. Among the 225 patients who received ide-cel, cytokine release syndrome occurred in 88%, with 5% having an event of grade 3 or higher, and investigator-identified neurotoxic effects occurred in 15%, with 3% having an event of grade 3 or higher. CONCLUSIONS: Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma who had received two to four regimens previously. The toxicity of ide-cel was consistent with previous reports. (Funded by 2seventy bio and Celgene, a Bristol-Myers Squibb company; KarMMa-3 ClinicalTrials.gov number, NCT03651128.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023. PMID: 36762851. doi:10.1056/NEJMoa2213614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。